ATHENEX INC (ATNX) Stock Price, Forecast & Analysis
USA - NASDAQ:ATNX - US04685N2027 - Common Stock
ATNX Key Statistics, Chart & Performance
The current stock price of ATNX is 0.2031 USD. In the past month the price decreased by -82.49%. In the past year, price decreased by -97.95%.
ATNX Latest News, Press Relases and Analysis
ATNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.83 | 397.78B | ||
| AMGN | AMGEN INC | 15.48 | 182.21B | ||
| GILD | GILEAD SCIENCES INC | 14.96 | 152.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.72 | 110.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.99 | 71.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 886.18 | 59.24B | ||
| INSM | INSMED INC | N/A | 40.94B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 9.53 | 23.39B | ||
| INCY | INCYTE CORP | 16.85 | 21.12B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.4 | 20.77B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.24 | 14.61B |
Related stock screener links
About ATNX
Company Profile
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 269 full-time employees. The company went IPO on 2017-06-14. The firm is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The firm's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.
Company Info
ATHENEX INC
1001 Main St Ste 600
Buffalo NEW YORK 14203 US
CEO: Johnson Y.N. Lau
Employees: 269
Phone: 17168988625.0
ATHENEX INC / ATNX FAQ
What does ATHENEX INC do?
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 269 full-time employees. The company went IPO on 2017-06-14. The firm is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The firm's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.
What is the current price of ATNX stock?
The current stock price of ATNX is 0.2031 USD. The price decreased by -23.39% in the last trading session.
Does ATNX stock pay dividends?
ATNX does not pay a dividend.
What is the ChartMill rating of ATHENEX INC stock?
ATNX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ATHENEX INC (ATNX) stock traded?
ATNX stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of ATHENEX INC (ATNX)?
ATHENEX INC (ATNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.88).
What is the market capitalization of ATNX stock?
ATHENEX INC (ATNX) has a market capitalization of 1.76M USD. This makes ATNX a Nano Cap stock.
ATNX Technical Analysis
ATNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATNX. ATNX has a bad profitability rating. Also its financial health evaluation is rather negative.
ATNX Financial Highlights
Over the last trailing twelve months ATNX reported a non-GAAP Earnings per Share(EPS) of -15.88. The EPS increased by 20.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATNX Forecast & Estimates
9 analysts have analysed ATNX and the average price target is 2.3 USD. This implies a price increase of 1029.99% is expected in the next year compared to the current price of 0.2031.
For the next year, analysts expect an EPS growth of 70.35% and a revenue growth -30.28% for ATNX